<div id="readability-page-1">Bioventus (BVS) is up  ~19% in Tuesday trading after posting Q3 financial results that beat on both lines.  While net sales change year-over-year was essentially flat due to a ~29% decline in its restorative therapies segment, the medical device company saw strong growth of, respectively, 6.4% and 9.3%, in its two largest businesses, pain treatment...</div>

<p>Bioventus (BVS) 的股价在发布第三季度财报后上涨了约 19%，该财报超出了预期。尽管由于修复疗法部门大幅下降 29%，导致同比净销售额变化持平，但公司在其两个最大领域——疼痛治疗和另一个未指明的领域——分别实现了 6.4% 和 9.3% 的显著增长</p>

Bioventus 因第三季度业绩超出预期而股价飙升